- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00962949
The Renin-Aldosterone Axis in Postural Tachycardia Syndrome
November 16, 2017 updated by: Satish R. Raj, Vanderbilt University Medical Center
The purpose of this study is to determine the role of the renin-angiotensin-aldosterone in the pathophysiology of postural tachycardia syndrome, and to provide an insight about the disease process in this disorder.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction Center criteria
- Age between 18-64 years
- Male or females are eligible
- Able and willing to provide informed consent
- Healthy control subjects with no major medical problem (including postural tachycardia syndrome), free of medications during the study
Exclusion Criteria:
- Overt cause of postural tachycardia e.g., dehydration
- Inability to give or withdraw informed consent
- Pregnancy
- Hypertension (BP > 140/90)
- Significant co-morbid condition
- Other factors which in the investigator's opinion would prevent the subject from completing the protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Control
Healthy controls
|
Angiotensin II infusion for 1 hour
|
Experimental: Postural Tachycardia Syndrome
Patients with Postural Tachycardia Syndrome
|
Angiotensin II infusion for 1 hour
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean Arterial Blood Pressure Change
Time Frame: 1 hour
|
1 hour
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma Renin Activity
Time Frame: 1 hour
|
1 hour
|
Aldosterone Level
Time Frame: 1 hour
|
1 hour
|
Cortisol Level
Time Frame: 1 hour
|
1 hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2009
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
August 18, 2009
First Submitted That Met QC Criteria
August 19, 2009
First Posted (Estimate)
August 20, 2009
Study Record Updates
Last Update Posted (Actual)
August 17, 2018
Last Update Submitted That Met QC Criteria
November 16, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Nervous System Diseases
- Disease
- Arrhythmias, Cardiac
- Cardiac Conduction System Disease
- Autonomic Nervous System Diseases
- Primary Dysautonomias
- Orthostatic Intolerance
- Syndrome
- Tachycardia
- Postural Orthostatic Tachycardia Syndrome
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Serine Proteinase Inhibitors
- Vasoconstrictor Agents
- Angiotensin II
- Giapreza
- Angiotensinogen
Other Study ID Numbers
- 081398
- PF334
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postural Orthostatic Tachycardia Syndrome (POTS)
-
New York Medical CollegeNational Institutes of Health (NIH)CompletedOrthostatic Intolerance | Postural Orthostatic Tachycardia Syndrome (POTS) | POTSUnited States
-
Mayo ClinicNot yet recruitingPostural Tachycardia Syndrome | Postural Orthostatic Tachycardia Syndrome | Autonomic Dysfunction | POTS - Postural Orthostatic Tachycardia SyndromeUnited States
-
Jami WarrenRecruitingPOTS - Postural Orthostatic Tachycardia SyndromeUnited States
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedPostural Tachycardia Syndrome (POTS)United States
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPostural Tachycardia Syndrome (POTS)United States
-
Lund UniversityRegion SkaneRecruitingPOTS - Postural Orthostatic Tachycardia SyndromeSweden
-
Nationwide Children's HospitalCompletedSyncope | Postural Orthostatic Tachycardia Syndrome (POTS)United States
-
New York Medical CollegeLundbeck LLCActive, not recruitingPostural Tachycardia Syndrome (POTS) | Fainting | Vasovagal Syncope (VVS)United States
-
argenxIqvia Pty LtdRecruitingPost-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia SyndromeUnited States
-
Assiut UniversityRecruitingPOTS - Postural Orthostatic Tachycardia SyndromeEgypt
Clinical Trials on Angiotensin II
-
Children's Hospital Medical Center, CincinnatiCompletedEosinophilic Esophagitis | Connective Tissue DisordersUnited States
-
Norwegian University of Science and TechnologyAstraZenecaCompleted
-
Massachusetts General HospitalCompletedHypertrophic CardiomyopathyUnited States
-
University of California, San FranciscoFlight Attendant Medical Research InstituteRecruitingCardiovascular Diseases | HypertensionUnited States
-
La Jolla Pharmaceutical CompanyCompletedSepsis | Catecholamine-resistant Hypotension (CRH) | Distributive Shock | High Output ShockUnited States, Canada, Belgium, Australia, United Kingdom, Finland, New Zealand, France, Switzerland, Germany
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyocardial Infarction | Hypertension | Atherosclerosis | Heart Failure, CongestiveUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyocardial Infarction | Hypertension | Atherosclerosis | Heart Failure, CongestiveUnited States
-
Nara Medical UniversityCompletedHypertension | Brain InfarctionJapan
-
Louise FaerchCompletedHypoglycemia | Type 1 DiabetesDenmark
-
NYU Langone HealthNot yet recruitingArthrofibrosis of KneeUnited States